We delineated the intra-tumor heterogeneity (ITH) and the relationship between tumor and stroma, which identified a RE1 silencing factor (REST)-mediated regulatory axis in a subset of patients that may have superior benefit from ICI therapy. This evidence concerns the gene REST and neoplasm.